DMD #30593

Introduction
carboxamide [ Flesch, 2004] . O xcarbazepine is rapidly r educed by c ytosolic arylketone reductases to the monohydroxy derivative (MHD) (figure 1) [Shuetz et al., 1986; Menge et al., 1983] . In humans, formation of MHD is stereoselective, with the two enantiomers formed in a ratio of 8 0% ( (S)-MHD) t o 2 0% ( (R)-MHD) [ Flesch e t al., 1992] . F ollowing oral administration of r adiolabeled OX C, on ly 2 % of t otal r adioactivity in p lasma is du e to unchanged OXC and approximately 70% is due to MHD [Shuetz et al., 1986] . Minor amounts of Oxcarbazepine are transformed in a sulfate conjugate and directly conjugated [Shuetz et al., 1986] . Minor amounts of MHD are oxidized to the inactive dihydroxy derivative (DHD). The anticonvulsant properties of MHD are possibly mediated through the effects on neuronal ion fluxes a nd spe cifically by blocking voltage dependent s odium c hannels [Schmutz e t a l., 1993] .
MHD is a potent anticonvulsive agent following p.o. and intramuscular administration. MHD is more soluble in water than OXC, the partition coefficients in n-octanol/aqueous buffer pH 7.4 at 25°C ar e 2 0.4 an d 8.8 for O XC an d M HD, re spectively. Therefore, i ntravenously administered MHD has been developed for the treatment of partial seizures.
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Since af ter o ral ad ministration al l ab sorbed O XC is rap idly an d almost co mpletely metabolized to t he monohydroxy de rivative M HD, a n assessment of the absolute or al bioavailability of OXC were performed using MHD as an i.v. reference. The objectives of this study was to assess tolerability of a single i.v. dose of MHD (racemate), the bioavailability of MHD after single oral administration of a 300 mg Trileptal ® tablet compared to a single i.v.
administration of 250 mg of MHD, the disposition of the two enantiomers of MHD in plasma after p.o. and i .v. administration. Two a dditional goals were to determine the pharmacokinetics in plasma and urine of the two enantiomers of MHD, as well as OXC and DHD, and to determine the degree of conjugation of MHD.
Materials and Methods
Study design and population
The st udy w as performed in tw o parts in th e H uman P harmacology Department at C ibaGeigy, Basel, Switzerland.
Part o ne wa s a pilot study i n th ree h ealthy a dult male volu nteers performed to assess the safety, tolerability and basic pharmacokinetics of single i. [Menge et al., 1983] .
For determination of MHD concentrations, blood samples were collected before (time point 0) and up to 72 h post single dose drug and up to 12 post final steady state administration. 4 mL of venous b lood w as drawn in to Lithium heparin Va cutainers® ( Becton Dikinson) a t th e following sampling points: Day 1 Predose (morning dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 32, 48, 56 and 7 2 hours po st d ose, o n day 7 P redose (evening do se), on day 8 P redose (morning dose), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours postdose. Immediately after blood withdrawal the tube was inverted gently several times to ensure the mixing of tube contents.
Prolonged sample contact was avoided with the rubber stopper. The tube was placed upright in a test tube rack surrounded by ice until centrifugation. The sample was centrifuged at 4°C for 10 minutes at approximately 1500 x gravity. At least 1.5 mL plasma was transferred to a polypropylene screw-cap tube and frozen within 60 minutes of venipuncture. The tubes were kept frozen at or below -15°C until assayed.
Drug analysis
For determination of OXC , M HD, DHD , ( S)-MHD a nd of (R)-MHD c oncentrations, b lood and urine samples were collected before drug administration and up to 72 h post dose. Blood samples 5.5 mL of v enous bl ood were dr awn into heparinized ® Monovette t ubes ( Sarstedt AG, Sewelen, Switzerland) at the following sampling points: 0, 1, 2, 3, 4, 6, 8, 10, 24, 32, 48, This article has not been copyedited and formatted. The final version may differ from this version. 1, 2, 3, 4, 6, 8, 10, 14, 32, 48, 56 and 72 h p.d. after start of infusion. Immediately after blood withdrawal, samples were centrifuged (2200 g for 5 minutes at room temperature), the plasma removed by pipette to plain po lypropylene tu bes a nd s tored at -80 C until a nalysis. U rine samples: All produced urine was collected up to 72 h p.d. in the following fractions: 0-3, 3-6, 6-10, 10-24, 24-32, 32-48, 48-56 and 56-72 hydrolysis. P lasma c oncentrations of M HD we re de termined using a va lidated highperformance liquid chromatography method and UV detection [Menge et al., 1983] . After the internal standard (CGP 23827, mol.wt. 252.27) 
Pharmacokinetic evaluation
After or al a dministration of OXC , the highest observed concentration of t he parent or its metabolites was designated C max , and the time at which this occurred relative to the time of 
Results
Validation of analytical method
This article has not been copyedited and formatted. The final version may differ from this version. Table 1 .
Pharmacokinetics results
A summary of all mean derived pharmacokinetic parameters from the first study are given in Table 2 The AU C va lues of M HD in creased with t he dose, v alues we re 109, 142 , 280 h(µmol/L) at dose levels of 150, 200 and 250 mg, respectively. Between 24.3 to 42.8 % of the dose was excreted as unchanged from 0 to 72 hours. A complete pharmacokinetic evaluation was not performed. As the 250 mg MHD iv dose gave plasma concentrations comparable to those o bserved pr eviously a fter a n o ral do se o f OXC of 300 mg, t hese tw o do ses w ere selected for the main study. In terms of AUC the enantiomeric ratio of S over R was between 1.2 and 1.6 indicating a different disposition between the two enantiomers of MHD. The total plasma c learance va lues we re 5. 4, 5. 5 and 3.5 L/h at dose le vels of 1 50, 200 and 250 mg, respectively. The renal clearance values of 1.3 to 1.7 L/h indicate that renal excretion is only a minor elimination pathway for free MHD. The mean (SD) model-independent parameters of R-and (S)-MHD after i.v. administration of MHD over 30 minutes are presented in Table 3 . This al most three-fold i ncrease in t he R t o S ratio b etween I V a nd PO ad ministration was highly s tatistically significant, a s ev idenced by the l ack o f o verlap between the co nfidence intervals.
Absolute bioavailability
This article has not been copyedited and formatted. The final version may differ from this version. 
DMD #30593
15 The absolute bioavailability of OXC was assessed from plasma data of MHD. Using the nonenantioselective a ssay c orrected f or t he a dministered dose, bi oavailability was 0.99. T hese data co nfirm t hat O XC g iven as a solid oral formulation, i s completely absorbed in ma n.
Mean (SD) f value are summarized in Table 4 . When OXC is administered orally, the ratio of the AUC values of (S)-MHD over (R)-MHD equals 3.8, ( or a n estimate of 3.9 with 90% CI=[3.3, 4.5] based on the statistical analysis), indicating a presystemic enantioselective reduction of the prochiral carbonyl group of OXC, with the (S)-MHD predominant in plasma. OXC is reduced by a carbonylreductase which is present in all mammalian species [Feldsted et al., 1980] . The formation of the S enantiomer of 
Discussion
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16 MHD can be predicted, u sing P relog's r ule [ Prelog e t al., 19 64] . T his r ule sta tes that if a ketone i s projected i n a p lane w ith t he largest g roup to the l eft, t he resulting al cohol will predominantly ha ve t he configuration w ith the hydroxy g roup a bove th e pl ane. T hese differences in the pharmacokinetics of the two enantiomers of MHD should not be clinically relevant, a s i t ha s b een demonstrated that b oth enantiomers ha ve si milar anticonvulsant efficacy and tolerability [Schmutz et al., 1993; Schmutz et al., 1994] .
MHD was given intravenously to hu mans f or the f irst time in th e present study. 
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The d ifferences in th e pharmacokinetics of th e t wo e nantiomers of M HD s hould n ot be clinically r elevant as both enantiomers h ave si milar antiepileptic efficacy and t olerability in animals [Schmutz et al., 1993] . 
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CL [L . h -1 ] - - 4.3(0.9) 3.1(0.6) - - - - CL R [L . h -1 ] - - 0.9(0.2) 0.9(0.2) - - - - t 1/2 [h] - - 9.0(1.5) 10.6(2.6) - - - - V ss [L] - -
